Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy
Targeted immunotherapies have emerged as a transformative approach in cancer treatment, offering enhanced specificity to tumor cells, and minimizing damage to healthy tissues. The targeted treatment of the tumor immune system has become clinically applicable, demonstrating significant anti-tumor act...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1271321/full |
| _version_ | 1797678193369415680 |
|---|---|
| author | Jianshu Zhu Jiawei Fan Yuanliang Xia Hengyi Wang Yuehong Li Zijia Feng Changfeng Fu |
| author_facet | Jianshu Zhu Jiawei Fan Yuanliang Xia Hengyi Wang Yuehong Li Zijia Feng Changfeng Fu |
| author_sort | Jianshu Zhu |
| collection | DOAJ |
| description | Targeted immunotherapies have emerged as a transformative approach in cancer treatment, offering enhanced specificity to tumor cells, and minimizing damage to healthy tissues. The targeted treatment of the tumor immune system has become clinically applicable, demonstrating significant anti-tumor activity in both early and late-stage malignancies, subsequently enhancing long-term survival rates. The most frequent and significant targeted therapies for the tumor immune system are executed through the utilization of checkpoint inhibitor antibodies and chimeric antigen receptor T cell treatment. However, when using immunotherapeutic drugs or combined treatments for solid tumors like osteosarcoma, challenges arise due to limited efficacy or the induction of severe cytotoxicity. Utilizing nanoparticle drug delivery systems to target tumor-associated macrophages and bone marrow-derived suppressor cells is a promising and attractive immunotherapeutic approach. This is because these bone marrow cells often exert immunosuppressive effects in the tumor microenvironment, promoting tumor progression, metastasis, and the development of drug resistance. Moreover, given the propensity of myeloid cells to engulf nanoparticles and microparticles, they are logical therapeutic targets. Therefore, we have discussed the mechanisms of nanomedicine-based enhancement of immune therapy through targeting myeloid cells in osteosarcoma, and how the related therapeutic strategies well adapt to immunotherapy from perspectives such as promoting immunogenic cell death with nanoparticles, regulating the proportion of various cellular subgroups in tumor-associated macrophages, interaction with myeloid cell receptor ligands, activating immunostimulatory signaling pathways, altering myeloid cell epigenetics, and modulating the intensity of immunostimulation. We also explored the clinical implementations of immunotherapy grounded on nanomedicine. |
| first_indexed | 2024-03-11T22:56:06Z |
| format | Article |
| id | doaj.art-eed843b18ed44d58af1cac8bbca5e7e3 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-11T22:56:06Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-eed843b18ed44d58af1cac8bbca5e7e32023-09-21T17:12:08ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-09-011410.3389/fphar.2023.12713211271321Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapyJianshu Zhu0Jiawei Fan1Yuanliang Xia2Hengyi Wang3Yuehong Li4Zijia Feng5Changfeng Fu6Department of Spine Surgery, The First Hospital of Jilin University, Changchun, ChinaDepartment of Gastroenterology, The First Hospital of Jilin University, Changchun, ChinaDepartment of Cardiac Surgery, The First Hospital of Jilin University, Changchun, ChinaDepartment of Spine Surgery, The First Hospital of Jilin University, Changchun, ChinaDepartment of Spine Surgery, The First Hospital of Jilin University, Changchun, ChinaDepartment of Spine Surgery, The First Hospital of Jilin University, Changchun, ChinaDepartment of Spine Surgery, The First Hospital of Jilin University, Changchun, ChinaTargeted immunotherapies have emerged as a transformative approach in cancer treatment, offering enhanced specificity to tumor cells, and minimizing damage to healthy tissues. The targeted treatment of the tumor immune system has become clinically applicable, demonstrating significant anti-tumor activity in both early and late-stage malignancies, subsequently enhancing long-term survival rates. The most frequent and significant targeted therapies for the tumor immune system are executed through the utilization of checkpoint inhibitor antibodies and chimeric antigen receptor T cell treatment. However, when using immunotherapeutic drugs or combined treatments for solid tumors like osteosarcoma, challenges arise due to limited efficacy or the induction of severe cytotoxicity. Utilizing nanoparticle drug delivery systems to target tumor-associated macrophages and bone marrow-derived suppressor cells is a promising and attractive immunotherapeutic approach. This is because these bone marrow cells often exert immunosuppressive effects in the tumor microenvironment, promoting tumor progression, metastasis, and the development of drug resistance. Moreover, given the propensity of myeloid cells to engulf nanoparticles and microparticles, they are logical therapeutic targets. Therefore, we have discussed the mechanisms of nanomedicine-based enhancement of immune therapy through targeting myeloid cells in osteosarcoma, and how the related therapeutic strategies well adapt to immunotherapy from perspectives such as promoting immunogenic cell death with nanoparticles, regulating the proportion of various cellular subgroups in tumor-associated macrophages, interaction with myeloid cell receptor ligands, activating immunostimulatory signaling pathways, altering myeloid cell epigenetics, and modulating the intensity of immunostimulation. We also explored the clinical implementations of immunotherapy grounded on nanomedicine.https://www.frontiersin.org/articles/10.3389/fphar.2023.1271321/fullnanomedicine systemsmyeloid cellsimmunotherapytumor immune microenvironmentosteosarcoma |
| spellingShingle | Jianshu Zhu Jiawei Fan Yuanliang Xia Hengyi Wang Yuehong Li Zijia Feng Changfeng Fu Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy Frontiers in Pharmacology nanomedicine systems myeloid cells immunotherapy tumor immune microenvironment osteosarcoma |
| title | Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy |
| title_full | Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy |
| title_fullStr | Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy |
| title_full_unstemmed | Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy |
| title_short | Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy |
| title_sort | potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy |
| topic | nanomedicine systems myeloid cells immunotherapy tumor immune microenvironment osteosarcoma |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1271321/full |
| work_keys_str_mv | AT jianshuzhu potentialtargetsandapplicationsofnanodrugtargetingmyeloidcellsinosteosarcomafortheenhancementofimmunotherapy AT jiaweifan potentialtargetsandapplicationsofnanodrugtargetingmyeloidcellsinosteosarcomafortheenhancementofimmunotherapy AT yuanliangxia potentialtargetsandapplicationsofnanodrugtargetingmyeloidcellsinosteosarcomafortheenhancementofimmunotherapy AT hengyiwang potentialtargetsandapplicationsofnanodrugtargetingmyeloidcellsinosteosarcomafortheenhancementofimmunotherapy AT yuehongli potentialtargetsandapplicationsofnanodrugtargetingmyeloidcellsinosteosarcomafortheenhancementofimmunotherapy AT zijiafeng potentialtargetsandapplicationsofnanodrugtargetingmyeloidcellsinosteosarcomafortheenhancementofimmunotherapy AT changfengfu potentialtargetsandapplicationsofnanodrugtargetingmyeloidcellsinosteosarcomafortheenhancementofimmunotherapy |